An experimental drug from Alector Inc. failed to slow the decline of patients with frontotemporal dementia in a late-stage ...
“To more accurately stage disease and track progression over time ... and confirmatory testing for the amyloid pathology is ...
This represents Alector's second failed neurodegenerative asset in a year, after an AbbVie-partnered asset missed in ...
Alzheimer's disease is notorious for scrambling patients' daily rhythms. Restless nights with little sleep and increased ...
Doug Whitney, 76, carries a rare PSEN2 genetic mutation that causes early-onset Alzheimer's but shows no cognitive decline ...
The blood-based test detects phosphorylated tau 181, a biomarker that is correlated with the presence of amyloid pathology in ...
Three years after Chris Long received his Alzheimer's diagnosis, he and his wife Janet are preparing for another Walk to End ...
Midland Reporter-Telegram on MSN
Craddick backs proposition to fund $3B dementia research institute
Rep. Tom Craddick and the Alzheimer’s Association urge voters to back Texas Proposition 14, creating DPRIT with $3B for ...
The Elecsys pTau181 blood test has been cleared to help rule out Alzheimer’s disease. The test correctly identified people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback